













82. Bikker A, van Woerkom JM, Kruize AA, et al. Increased expression of IL-7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation. *Arthritis Rheum* 2010;62:969-77.
83. Weng MY, Huang YT, Liu MF, Lu TH. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren's syndrome in Taiwan. *Ann Rheum Dis* 2012;71:524.
84. Johnsen SJ, Brun JG, Goransson LG, et al. Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: A population based study. *Arthritis Care Res* 2013;65:816-21.
85. Grigoriadou S, Chowdhury F, Pontarini E, et al. B-cell depletion with rituximab in the treatment of primary Sjögren's syndrome: what have we learnt? *Clin Exp Rheumatol* 2019;37:S217-24.
86. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2010;62:960-8.
87. Pijpen J, Van Imhoff GW, Spijkervet FKL, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. *Arthritis Rheum* 2005;52:2740-50.
88. Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. *Arthritis Res Ther* 2013;15:R172.
89. Clairew S, Levesque MC, Prak ETL, et al. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. *Arthritis Rheum* 2013;65:1097-106.
90. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. *Ann Rheum Dis* 2008;67:1541-4.
91. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). *Arthritis Rheum* 2007;57:310-7.
92. Devauchelle-Pensec V, Mariette X, Jousse-Joulins J, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. *Ann Intern Med* 2014;160:233-42.
93. Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren's syndrome. *Arthritis Rheumatol* 2017;69:1440-50.
94. Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjögren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. *Ann Rheum Dis* 2009;68:284-5.
95. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. *Ann Rheum Dis* 2012;71:1297-02.
96. Gottemberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. *Ann Rheum Dis* 2013;72:1026-31.
97. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. *Ann Rheum Dis* 2010;69:1103-9.
98. Fasano S, Gordon P, Hajji R, et al. Rituximab in the treatment of inflammatory myopathies: a review. *Rheumatology* 2016;56:26-36.
99. Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. *Rheumatology (Oxford)* 2009;48:968-71.
100. Allenbach Y, Guiguet M, Rigolet A, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II Trial. *PLoS One* 2015;10:e0133702.
101. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. *Curr Rheumatol Rep* 2003;5:425-30.
102. Vandembroucke E, Grutters JC, Altenburg J, et al. Rituximab in life threatening antisynthetase syndrome. *Rheumatol Int* 2009;29:1499-502.
103. Rider LG, Yip AL, Horkayne-Szakaly I, et al. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the rituximab in myositis trial. *Clin Exp Rheumatol* 2014;32:689-96.
104. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. *Arch Dermatol* 2007;143:763-7.
105. Barsotti S, Cioffi E, Tripoli A, et al. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. *Reumatismo* 2018;70:1011.
106. Aggarwal R, Loganathan P, Koontz A, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. *Rheumatology* 2016;56:247-54.
107. De Souza FHC, Miozzi R, de Moraes JCB, et al. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. *Adv Rheumatol* 2018;58:31.
108. Landewé RBM, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 *Ann Rheum Dis* [published online June 5, 2020]. doi:10.1136/annrheumdis-2020-217877.

Non-commercial use only